Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19

Overview of attention for article published in Frontiers in immunology, December 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog
policy: 1 policy source

twitter: 4 X users
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 51 Mendeley

Summary News Blogs Policy documents X Wikipedia Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 69,561 followers.

Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19 https://t.co/hRKPCeksgS

23 Dec 2021

Reply Repost Favourite

RT @BagaiDr: Preclinical Immune Respons,Safety Evaluation-Protein Subunit Vac Nanocovax for COVID19:recombinant protein tech to produce ext…

07 Dec 2021

Reply Repost Favourite

Preclinical Immune Respons,Safety Evaluation-Protein Subunit Vac Nanocovax for COVID19:recombinant protein tech to produce extracellular(soluble)portion S protein of SARSCoV2;gene encod S protein S protein extracell domain.CHO-S cell-highest S protein expr

07 Dec 2021

Reply Repost Favourite

New Research: Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19: The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)… https://t.co

06 Dec 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.